



**In the Claims:**

1. (canceled)
2. (original) A method of treating diseases mediated by *Mycobacterium*, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.
3. (previously presented) A method according to claim 2 wherein *Mycobacterium* is *Mycobacterium tuberculosis*.
4. (previously presented) A method according to claim 2 wherein a pleuromutilin is a compound comprising the basic structural elements as set out in formula




wherein R is vinyl or ethyl and the dotted line is a bond or is no bond.


5. (currently amended) [[Use or a]] A method according to claim 4 wherein a pleuromutilin is selected from the group consisting of
  - a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula




- a compound of formula



- a compound of formula




- a compound of formula



and

- a compound of



6. (withdrawn) A compound selected from the group consisting of compounds of formulae as set out in TABLE 1:

TABLE 1










	
	
	
	

TABLE 1

<p>and</p>	

7. (withdrawn) A compound of formula



wherein

- the dotted line is a bond (double bond between positions a=b),  $R_{1A}$  is hydrogen and  $R_{2A}$  is not present,

or

- the dotted line is no bond (single bond between positions a-b) and  $R_{1A}$  and  $R_{2A}$  independently of each other are hydrogen, halogen or deuterium,

$R_{3A}$  is  $(C_{1-6})$ alkyl,

$R_{4A}$  is hydrogen,  $(C_{1-6})$ alkyl, a group  $-C(=NH)-NH_2$ , or the residue of an amino acid,

$R_{5A}$  is hydrogen, or


$R_{4A}$  and  $R_{5A}$  together are a group  $=CH-NH_2$ ,

$R_{6A}$  is hydrogen or deuterium, and

$m_A$  is 0, 1, 2, 3, 4, or 5.

8. (withdrawn) A 14-O-(oximino- $(C_{3-8})$ cycloalkyl-sulfanylmethylcarbonyl)-pleuromutilin and a 14-O-(hydrazono- $(C_{3-8})$ cycloalkyl-sulfanylmethylcarbonyl)-pleuromutilin.

9. (withdrawn) A compound of formula



wherein

$R_{1B}$  has the meaning of  $R_{1A}$  as defined in claim 7,

$R_{2B}$  has the meaning of  $R_{2A}$  as defined in claim 7,

$R_{10B}$  has the meaning of  $R_{6A}$  as defined in claim 7,

the dotted line has the meaning as defined in claim 7,

$m_B$  has the meaning of  $m_a$  as defined above,

$R_{3B}$  is hydrogen or  $(C_{1-6})$ alkyl,

$X_B$  is  $-O-R_{4B}$  or  $-NR_{5B}R_{6B}$ ,

$R_{4B}$  is hydrogen or  $(C_{1-6})$ alkyl, optionally substituted by a group  $-NR_{7B}R_{8B}$ ,


$R_{5B}$  and  $R_{6B}$  independently of each other are  $(C_{1-4})$ alkyl,

$R_{7B}$  and  $R_{8B}$  independently of each other are  $(C_{1-4})$ alkyl, or

$R_{7B}$  and  $R_{8B}$  together with the nitrogen atom to which they are attached form aliphatic heterocyclyl, having 5 to 8 ring members, and

$R_{9B}$  is hydrogen or  $(C_{1-4})$ alkyl.

10. (withdrawn) A compound of formula



wherein

$R_{1C}$  has the meaning of  $R_{1A}$  as defined in claim 7,

$R_{2C}$  has the meaning of  $R_{2A}$  as defined in claim 7,


the dotted line has the meaning as defined in claim 7,

$R_{4C}$  has the meaning of  $R_{6A}$  as defined in claim 7, and



R<sub>3C</sub> is amino, (C<sub>1-4</sub>)alkylamino, di(C<sub>1-4</sub>)alkylamino, the residue of an amino acid, hydroxy, or (C<sub>1-4</sub>)alkoxy.

11. (withdrawn) A compound of formula



wherein

R<sub>1D</sub> has the meaning of R<sub>1A</sub> as defined in claim 7,

R<sub>2D</sub> has the meaning of R<sub>2A</sub> as defined in claim 7,

R<sub>4D</sub> has the meaning of R<sub>6A</sub> as defined in claim 7,

the dotted line has the meaning as defined in claim 7, and

R<sub>3D</sub> is aliphatic heterocyclyl of 4 to 8 ring members, and comprising one nitrogen atom as the heteroatom, or (C<sub>4-8</sub>)cycloalkyl, which heterocyclyl or cycloalkyl is substituted by hydroxy or oxo.

12. (withdrawn) A compound of claim 7 in the form of a salt.

13. (withdrawn) A compound of claim 7 for use as a pharmaceutical.

14. (withdrawn) A pharmaceutical composition comprising a compound of claim 7 in association with at least one pharmaceutical excipient.

15. (withdrawn) A pharmaceutical composition according to claim 13, further comprising another pharmaceutically active agent.

16. (withdrawn) A pharmaceutical composition comprising a pleuromutilin in association with at least one pharmaceutical excipient, and further comprising another pharmaceutically active agent useful in the treatment of Mycobacterium infections.
17. (withdrawn) A compound of claim 7 for use in the preparation of a medicament for the treatment of microbial diseases.
18. (previously presented) A method of treatment of microbial diseases, which method comprises administering to a subject in need of such treatment an effective amount of a compound of claim 7.